In Vitro and In Vivo Evaluation of Oxatomide β-Cyclodextrin Inclusion Complex

Table 2

Pharmacokinetic parameters of oxatomide in rabbits (𝑛=8) after administration of a single oral dose (5 mg/kg) of oxatomide-β-cyclodextrin-PVPK15 complex and commercial oxatomide product.

Parameter	Oxatomide-𝛽-cyclodextrin-PVPK15 complex	Commercial oxatomide product
𝐶max (ng/mL)*	127.23 ± 6.180	141.16 ± 10.99
𝑇max (hr)	4.50 ± 0.925	4.00 ± 0.00
AUC0-48 (ng·hr/mL)*	1586.90 ± 84.00	957.10 ± 57.00
AUC0-∞(ng·hr/mL)*	1662.14 ± 127.06	962.85 ± 57.61
𝐾el, (hr^−1)*	0.074 ± 0.016	0.133 ± 0.028
Relative bioavailability (%)	173.15 ± 16.53	—

Each value represents the mean ± standard division of eight rabbits.
* 𝑃<0.05 based on Student’s 𝑡-test, statistically significant difference between oxatomide-𝛽-cyclodextrin-PVPK15 complex and commercial oxatomide product.